Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT05133661

SUCCESS - Feasibility of HPV Testing and Treatment of Pre-cancerous Cervical Cancer Lesions (HPV Study)

The goal is to assess the feasibility and acceptability of integrating into existing health systems, provision of HPV screening and treatment of pre-cancerous cervical cancer lesions with ablative treatments in Burkina Faso, Côte d'Ivoire, Guatemala, and the Philippines. Study findings will inform implementation of cervical cancer prevention and treatment services as part of a global effort to eliminate cervical cancer, with particular relevance for low-and-middle income countries. This will inform country strategy and guidelines on offering integrated cervical cancer prevention and treatment services in a manner that is culturally sensitive, client oriented, and system appropriate.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

Age range

25 year–49 year

Sex eligibility

All sexes

Study type

Observational

Primary location

CMA de Do, Ouagadougou, Burkina Faso

Loading trial locations.

About this study

Research question:

  • How feasible is it to implement integrated HPV testing (including self-collection of samples) and ablative treatment of lesions precancerous cervical cancer lesions among HPV+ women aged 30-49 years (general population) and 25-49 years (WLHIV), leveraging on the existing health systems in the four study countries?
  • What is the acceptability of HPV screening through self-collection or clinician collection of sample, and ablative treatment of precancerous lesions among women accessing cervical cancer services in the study sites?
  • What is the cost of implementing integrated cervical cancer screening and precancer treatment services (Supply: counselling, HPV testing, treatment, training health care providers, etc.), and user-related costs (travel, out of pocket expenses opportunity costs, etc.) in the SUCCESS project supported sites?
  • Which factors influence the successful implementation of integrated HPV screening and treatment services (e.g. perceptions, experience of care, religious beliefs, culture, individual characteristics, availability of services, cost, etc.)?

Methodology:

We will utilize a hybrid effectiveness implementation Type III study design, using mixed methods approach. In Phase I, 2,227 women are enrolled in health facilities in each of the four countries (disaggregated by general population and WLHIV) and follow those who are HPV positive to determine the completion of screen-to-treat within three months. In Phase II focusing on community self-sampling, 8,694 are enrolled in Burkina Faso, Guatemala and the Philippines.

Quantitative and qualitative data will be collected from clients, service providers, key stakeholders, and secondary analysis of service delivery including laboratory data will be analyzed to assess acceptability and feasibility of implementing integrated cervical cancer screening and treatment services.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Women: Participants will be women residing in the study area, seeking services at SUCCESS project-supported health facilities, and meet the eligibility criteria to be enrolled in one of the components of the study (i.e, prospective component, client exit interviews and/or in-depth interviews).
  • Service providers: Health care personnel working in the project facilities at the time of the study providing services related to cervical cancer screening and treatment. Facility in-charges and laboratory personnel are included in this category.
  • Key informants: Health program managers, and community mobilizers at either local or national level in Burkina Faso, Cote d'Ivoire, Guatemala, and Philippines.
  • Men: Male members of the community (married or cohabiting with female partners) to gather their perspectives on the implementation of the cervical cancer prevention and treatment activities.

Exclusion criteria

  • Pregnant women
  • Individuals unwilling to participate or unable to provide informed consent

Treatment and study plan

HPV testing

Diagnostic Test

Interviews will be conducted among women from the general population and HIV+ women after screening for HPV. A small subset of participants will be interviewed after receiving treatment for precancer. HPV test results and outcome of the precancer treatment if indicated will be documented.

Other names: Thermal ablation of precancerous lesion

Primary outcomes

  1. Percentage of HPV positive women who complete screen to treatment within 3 months

    Time frame: Three months

    Proportion of HPV positive women who undergo treatment for precancerous cervical lesions within three months of screening

Secondary outcomes

  1. Acceptability - Percentage of women screened for HPV who report positive experience of care

    Time frame: 18 months

    Assess the adoption, satisfaction, and uptake of the cervical cancer services by the users and the providers

  2. Feasibility - Turnaround time from screening to treatment

    Time frame: 18 months

    Assess the adoption and practicability of providing the cervical cancer services through the mechanisms that exist in of each of the four countries

  3. Unit cost of providing HPV screening and treatment of precancerous cervical cancer lesion

    Time frame: 18 months

    The cost of providing the services and the user costs

Sponsors and collaborators

Lead sponsor

Jhpiego

Other

Collaborators

  • Expertise France
  • UNITAID
  • World Health Organization

Registry information

Official study title

Feasibility and Acceptability of Implementing Integrated HPV Testing and Treatment of Pre-cancerous Cervical Cancer Lesions in Burkina Faso, Côte d'Ivoire, Guatemala, and the Philippines

Acronym: HPV

Important dates

Study start
2022
Primary completion
2025
Study completion
2025
First posted
Nov 24, 2021
Registry last updated
Sep 17, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.